{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:17:45Z","timestamp":1789107465296,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clml.2024.07.014","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T21:20:35Z","timestamp":1723065635000},"page":"852-862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pomalidomide\/Daratumumab\/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014"],"prefix":"10.1016","volume":"24","author":[{"given":"Nizar J.","family":"Bahlis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Reece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sebag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Matous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-0376","authenticated-orcid":false,"given":"Jes\u00fas G.","family":"Berdeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Shustik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-762X","authenticated-orcid":false,"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0786-7961","authenticated-orcid":false,"given":"Kevin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Seet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirelis","family":"Acosta-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Quick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5352-9530","authenticated-orcid":false,"given":"Gustavo","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gentili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3604-2574","authenticated-orcid":false,"given":"David","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.07.014_bib0001","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/bmt.2015.307","article-title":"Evolving paradigms in the treatment of relapsed\/refractory multiple myeloma: increased options and increased complexity","volume":"51","author":"Cornell","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2024.07.014_bib0002","unstructured":"National Cancer Institute. Cancer stat facts: myeloma. Accessed 7 June 2023. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"10.1016\/j.clml.2024.07.014_bib0003","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/2040620718775629","article-title":"Update on the role of lenalidomide in patients with multiple myeloma","volume":"9","author":"Holstein","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2024.07.014_bib0004","article-title":"Multiple myeloma: an overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat Care Soc Pract"},{"key":"10.1016\/j.clml.2024.07.014_bib0005","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/blood-2017-03-726703","article-title":"How I treat first relapse of myeloma","volume":"130","author":"Harousseau","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.07.014_bib0006","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3324\/haematol.2016.148882","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"101","author":"Sonneveld","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.07.014_bib0007","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/17474086.2019.1634541","article-title":"Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials","volume":"12","author":"Martino","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2024.07.014_bib0008","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.07.014_bib0009","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.07.014_bib0010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/leu.2014.238","article-title":"In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone","volume":"29","author":"Ocio","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.07.014_bib0011","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2014-11-611426","article-title":"Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets","volume":"125","author":"Sehgal","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.07.014_bib0012","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.16213","article-title":"Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure","volume":"188","author":"Siegel","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.07.014_bib0013","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/s41375-020-0813-1","article-title":"Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment","volume":"34","author":"Siegel","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.07.014_bib0014","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/10428194.2022.2030477","article-title":"Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial","volume":"63","author":"Bahlis","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.07.014_bib0015","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-20-1781","article-title":"Immunomodulation in pomalidomide, dexamethasone, and daratumumab-treated patients with relapsed\/refractory multiple myeloma","volume":"26","author":"Pierceall","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2024.07.014_bib0016","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.07.014_bib0017","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.07.014_bib0018","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","article-title":"Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02","volume":"121","author":"Leleu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.07.014_bib0019","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.07.014_bib0020","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41375-020-01021-3","article-title":"Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse","volume":"35","author":"Dimopoulos","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.07.014_bib0021","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.07.014_bib0022","doi-asserted-by":"crossref","unstructured":"Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. Blood. 2017;130:974-981. doi: 10.1182\/blood-2017-05-785246","DOI":"10.1182\/blood-2017-05-785246"},{"key":"10.1016\/j.clml.2024.07.014_bib0023","unstructured":"Janssen. Darzalex\u00ae (daratumumab) prescribing information. 2023. Available at: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/DARZALEX-pi.pdf. Accessed 8 June 2023."},{"key":"10.1016\/j.clml.2024.07.014_bib0024","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2024.07.014_bib0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.07.014_bib0026","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.07.014_bib0027","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.07.014_bib0028","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.07.014_bib0029","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1182\/blood-2022-163483","article-title":"Subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) alone in patients with relapsed or refractory multiple myeloma (RRMM): overall survival results from the phase 3 Apollo study","volume":"140","author":"Dimopoulos","year":"2022","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T07:47:58Z","timestamp":1732520878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2152265024002854"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pomalidomide\/Daratumumab\/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}